Thousands of vulnerable Britons are receiving heavily discounted cannabis prescriptions in the UK for anxiety and depression. Leading psychiatrists have raised serious concerns about the mental health risks.

Private clinics now dominate the medical marijuana landscape in Britain. They dispense 99 per cent of all cannabis products in the country. Many are offering substantial discounts to benefits claimants. This makes powerful cannabis products more accessible than ever before.

Cannabis Prescriptions Numbers Soar to Record Levels

The figures paint a startling picture. Unlicensed cannabis prescriptions in the UK surged from 282,920 in 2023 to 659,293 in 2024. That represents nearly 10 tonnes of cannabis, a 133% increase in just one year.

Freedom of Information data reveals the trend is accelerating. In the first two months of 2025 alone, 88,214 unlicensed products were prescribed.

Specialist pharmacies are now offering close to 10,000 different cannabis products. Critics describe this as a pseudo-recreational market operating within legal loopholes.

Expert Warnings on Medical Marijuana Britain Safety

Sir Robin Murray is professor of psychiatric research at King’s College London. He has described the situation as “outrageous”. He’s particularly concerned about the increasingly powerful products being dispensed.

“These super-strength products carry an increased risk of dependence and psychiatric side effects,” Professor Murray warned.

His criticism of cannabis prescriptions in the UK for mental health conditions is stark. “There are no randomised controlled trials showing that cannabis benefits psychiatric disorders, and there is a lot of evidence that it causes them.”

He compared using cannabis for depression to drinking alcohol to cope. It might provide temporary relief but ultimately makes things worse.

NHS Concerns

The NHS itself warns that marijuana substantially raises the likelihood of developing severe mental health problems. This creates a troubling paradox. Patients seeking treatment for anxiety and depression may receive substances that could worsen their symptoms.

Despite these warnings, the barriers to obtaining cannabis prescriptions in the UK remain remarkably low. Many private clinics require only a single video consultation before dispensing products. Some proudly advertise next-day delivery straight to patients’ doors.

The Discount Dilemma

The practice of offering discounts to benefits claimants has raised additional concerns. Proponents argue this improves access to treatment. However, critics worry it may encourage vulnerable individuals to pursue medical marijuana Britain products without adequate consideration of the risks.

Private clinics have capitalised on legal loopholes. These allow them to prescribe unlicensed cannabis products far more readily than traditional NHS channels. This has created a booming market that operates largely outside conventional medical oversight.

Regulatory Questions

The rapid expansion has outpaced regulatory frameworks designed to ensure patient safety. Unlike licensed medications that undergo rigorous clinical trials, many of these products are dispensed with minimal evidence. There’s little proof supporting their efficacy for mental health conditions.

The concentration of prescribing in the private sector is striking. It accounts for 99 per cent of all medical marijuana Britain dispenses. This has created a system that bears little resemblance to traditional medical practice.

Prescription numbers continue to climb, and products are becoming stronger. Pressure is mounting on regulators to address what many experts view as a significant public health concern. The question remains whether current safeguards are sufficient. Can they protect vulnerable patients seeking relief from mental health conditions?

Source: dbrecoveryresources